Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial

I. Láng, R. Bell, F. Y. Feng, R. I. Lopez, J. Jassem, V. Semiglazov, N. Al-Sakaff, D. Heinzmann, J. Chang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims: Trastuzumab, in combination with chemotherapy, is the standard of care for patients with early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The Retreatment after HErceptin Adjuvant trial assessed the efficacy and safety of trastuzumab plus a taxane as first-line treatment for patients with metastatic breast cancer (MBC) who had relapsed after adjuvant trastuzumab for HER2-positive early breast cancer. Materials and methods: In total, 43 patients with HER2-positive MBC who had received previous adjuvant trastuzumab for ≥10 months, with a relapse-free interval of ≥6 months after the last adjuvant trastuzumab dose, were recruited. Eligible patients (n=41) were assigned to receive trastuzumab, either weekly or every 3 weeks, in combination with docetaxel or paclitaxel until disease progression. Results: At the final analysis, with a median follow-up time of 40 months, a positive response was observed in 25/41 patients (61%; 95% confidence interval: 48.7-80.4%), stable disease in 7/41 (17.1%) and progressive disease in 6/41 (14.6%). Three patients had missing response assessments (one had no measurable lesions at baseline and two had no post-baseline tumour assessments). The median progression-free survival (PFS) was 8.0 months (95% confidence interval: 6-11 months) and the median overall survival was 25.0 months (16-33 months). No correlation was found between response rate, PFS or overall survival and the duration of adjuvant trastuzumab treatment, trastuzumab-free interval, relapse-free interval, hormone receptor status or type of pre-metastatic treatment. The most common adverse events (all grades) were alopecia (32%) and diarrhoea (32%). Six patients (14.6%) developed at least one serious adverse event. No congestive heart failure or any unexpected adverse events were reported. Conclusion: Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalClinical Oncology
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Retreatment
Breast Neoplasms
Recurrence
Therapeutics
docetaxel
Disease-Free Survival
Trastuzumab
human ERBB2 protein
Confidence Intervals
Survival
Alopecia
Standard of Care
Paclitaxel
Combination Drug Therapy
Disease Progression
Diarrhea
Heart Failure
Hormones

Keywords

  • HER2-positive
  • Metastatic breast cancer
  • Retreatment
  • Taxane
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer : Final results of the retreatment after herceptin adjuvant trial. / Láng, I.; Bell, R.; Feng, F. Y.; Lopez, R. I.; Jassem, J.; Semiglazov, V.; Al-Sakaff, N.; Heinzmann, D.; Chang, J.

In: Clinical Oncology, Vol. 26, No. 2, 02.2014, p. 81-89.

Research output: Contribution to journalArticle

Láng, I. ; Bell, R. ; Feng, F. Y. ; Lopez, R. I. ; Jassem, J. ; Semiglazov, V. ; Al-Sakaff, N. ; Heinzmann, D. ; Chang, J. / Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer : Final results of the retreatment after herceptin adjuvant trial. In: Clinical Oncology. 2014 ; Vol. 26, No. 2. pp. 81-89.
@article{2282db26bf88479596bd101f4a85e020,
title = "Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial",
abstract = "Aims: Trastuzumab, in combination with chemotherapy, is the standard of care for patients with early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The Retreatment after HErceptin Adjuvant trial assessed the efficacy and safety of trastuzumab plus a taxane as first-line treatment for patients with metastatic breast cancer (MBC) who had relapsed after adjuvant trastuzumab for HER2-positive early breast cancer. Materials and methods: In total, 43 patients with HER2-positive MBC who had received previous adjuvant trastuzumab for ≥10 months, with a relapse-free interval of ≥6 months after the last adjuvant trastuzumab dose, were recruited. Eligible patients (n=41) were assigned to receive trastuzumab, either weekly or every 3 weeks, in combination with docetaxel or paclitaxel until disease progression. Results: At the final analysis, with a median follow-up time of 40 months, a positive response was observed in 25/41 patients (61{\%}; 95{\%} confidence interval: 48.7-80.4{\%}), stable disease in 7/41 (17.1{\%}) and progressive disease in 6/41 (14.6{\%}). Three patients had missing response assessments (one had no measurable lesions at baseline and two had no post-baseline tumour assessments). The median progression-free survival (PFS) was 8.0 months (95{\%} confidence interval: 6-11 months) and the median overall survival was 25.0 months (16-33 months). No correlation was found between response rate, PFS or overall survival and the duration of adjuvant trastuzumab treatment, trastuzumab-free interval, relapse-free interval, hormone receptor status or type of pre-metastatic treatment. The most common adverse events (all grades) were alopecia (32{\%}) and diarrhoea (32{\%}). Six patients (14.6{\%}) developed at least one serious adverse event. No congestive heart failure or any unexpected adverse events were reported. Conclusion: Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy.",
keywords = "HER2-positive, Metastatic breast cancer, Retreatment, Taxane, Trastuzumab",
author = "I. L{\'a}ng and R. Bell and Feng, {F. Y.} and Lopez, {R. I.} and J. Jassem and V. Semiglazov and N. Al-Sakaff and D. Heinzmann and J. Chang",
year = "2014",
month = "2",
doi = "10.1016/j.clon.2013.08.011",
language = "English",
volume = "26",
pages = "81--89",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

T2 - Final results of the retreatment after herceptin adjuvant trial

AU - Láng, I.

AU - Bell, R.

AU - Feng, F. Y.

AU - Lopez, R. I.

AU - Jassem, J.

AU - Semiglazov, V.

AU - Al-Sakaff, N.

AU - Heinzmann, D.

AU - Chang, J.

PY - 2014/2

Y1 - 2014/2

N2 - Aims: Trastuzumab, in combination with chemotherapy, is the standard of care for patients with early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The Retreatment after HErceptin Adjuvant trial assessed the efficacy and safety of trastuzumab plus a taxane as first-line treatment for patients with metastatic breast cancer (MBC) who had relapsed after adjuvant trastuzumab for HER2-positive early breast cancer. Materials and methods: In total, 43 patients with HER2-positive MBC who had received previous adjuvant trastuzumab for ≥10 months, with a relapse-free interval of ≥6 months after the last adjuvant trastuzumab dose, were recruited. Eligible patients (n=41) were assigned to receive trastuzumab, either weekly or every 3 weeks, in combination with docetaxel or paclitaxel until disease progression. Results: At the final analysis, with a median follow-up time of 40 months, a positive response was observed in 25/41 patients (61%; 95% confidence interval: 48.7-80.4%), stable disease in 7/41 (17.1%) and progressive disease in 6/41 (14.6%). Three patients had missing response assessments (one had no measurable lesions at baseline and two had no post-baseline tumour assessments). The median progression-free survival (PFS) was 8.0 months (95% confidence interval: 6-11 months) and the median overall survival was 25.0 months (16-33 months). No correlation was found between response rate, PFS or overall survival and the duration of adjuvant trastuzumab treatment, trastuzumab-free interval, relapse-free interval, hormone receptor status or type of pre-metastatic treatment. The most common adverse events (all grades) were alopecia (32%) and diarrhoea (32%). Six patients (14.6%) developed at least one serious adverse event. No congestive heart failure or any unexpected adverse events were reported. Conclusion: Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy.

AB - Aims: Trastuzumab, in combination with chemotherapy, is the standard of care for patients with early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The Retreatment after HErceptin Adjuvant trial assessed the efficacy and safety of trastuzumab plus a taxane as first-line treatment for patients with metastatic breast cancer (MBC) who had relapsed after adjuvant trastuzumab for HER2-positive early breast cancer. Materials and methods: In total, 43 patients with HER2-positive MBC who had received previous adjuvant trastuzumab for ≥10 months, with a relapse-free interval of ≥6 months after the last adjuvant trastuzumab dose, were recruited. Eligible patients (n=41) were assigned to receive trastuzumab, either weekly or every 3 weeks, in combination with docetaxel or paclitaxel until disease progression. Results: At the final analysis, with a median follow-up time of 40 months, a positive response was observed in 25/41 patients (61%; 95% confidence interval: 48.7-80.4%), stable disease in 7/41 (17.1%) and progressive disease in 6/41 (14.6%). Three patients had missing response assessments (one had no measurable lesions at baseline and two had no post-baseline tumour assessments). The median progression-free survival (PFS) was 8.0 months (95% confidence interval: 6-11 months) and the median overall survival was 25.0 months (16-33 months). No correlation was found between response rate, PFS or overall survival and the duration of adjuvant trastuzumab treatment, trastuzumab-free interval, relapse-free interval, hormone receptor status or type of pre-metastatic treatment. The most common adverse events (all grades) were alopecia (32%) and diarrhoea (32%). Six patients (14.6%) developed at least one serious adverse event. No congestive heart failure or any unexpected adverse events were reported. Conclusion: Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy.

KW - HER2-positive

KW - Metastatic breast cancer

KW - Retreatment

KW - Taxane

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84892487804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892487804&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2013.08.011

DO - 10.1016/j.clon.2013.08.011

M3 - Article

C2 - 24051172

AN - SCOPUS:84892487804

VL - 26

SP - 81

EP - 89

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 2

ER -